Oncolytics Biotech Inc T.ONC

Another off shelf CAR-T had durability problems

[askretka]

Not sure if this was posted here yet?

https://www.biopharmadive.com/news/nkarta-acute-myeloid-leukemia-nk-cell-results/654083/

Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!

[Noteable]

" Promising early remission rates haven’t yet translated to the types of long-lasting benefits associated with CAR-T therapies, leading to lingering questions about their durability and effectiveness. " Take note that this particular therapy is a CAR-NK cell therapy, and not specifially CAR-T therapy. "Nkarta believes the results with the newer regimen are “very meaningful

[Noteable]

" While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer (NK) cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic

[Noteable]

NKarta Bioscience's CEO Paul Hastings' incompetence is further witnessed by his former leadership of QLT Inc. https://www.linkedin.com/in/paul-hastings-25365a6/details/experience/

[Noteable]

NKarta Bioscience's CEO Paul Hastings lack luster tenure at the company has taken NKarta's stock price from US$62.00 in 2021 to US$2.00 today.